Latest Conference Articles

As the first medication designed to treat primary progressive multiple sclerosis moves closer to the market there are still many questions about how effective it will be and what other treatment options may look like in the future.

Prior research has shown women suffering from multiple sclerosis (MS) often have a more benign initial course than male patients. However, these same female patients tend to quickly transition to secondary progressive disease as their approach menopause.

In research presented at the ACTRIMS Forum in New Orleans, researchers raised an intriguing question: why has the median time of onset to diagnosis of MS increased for veterans of the Gulf War?

Canadian researchers found that a small percentage of MS patients tested positive for Lyme disease.

Magnetic Resonance Imaging (MRI) has long been the immediate go-to for “proof-of-concept†outcome measures in relapse-remitting multiple sclerosis (RRMS). After all, why fix what isn’t broken?

MRI scans were surprisingly lacking in sensitivity when it came to tracking the progress of MS. National Institutes of Health researchers came up with a new scale of measurement.

Obesity, along with the composition of the microbiome in the gut, have been suggested as being elements that may contribute to the risk of multiple sclerosis. Patients surveyed said they would be willing to change diet to see if it helped their illness.

For many years there were no approved treatments for patients with primary progressive multiple sclerosis. Recently, a concerted effort has been made to change that and get this patient population the help they so badly need.

Results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulators for relapsing multiple sclerosis (MS) patients showed significant reductions in the cumulative number of total gadolinium-enhancing (GdE) lesions.

In vivo detection, monitoring chronic inflammation, and repair/remyelination are all important in identifying biological targets and developments of new treatments in multiple sclerosis (MS).

Study results show that patients with multiple sclerosis may benefit from taking vitamin D3.

The US Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (Ocrevust/Roche).

Managing the cognitive impairment in patients suffering from multiple sclerosis (MS), has long been an integral focus of MS research.

Francisco Sylvester, MD, UNC School of medicine emphasized the importance of applying study findings to early interventions in treatment.

Francisco A. Sylvester, MD, UNC School of Medicine talked about the different ways in which the care of pediatric IBD differs from adult IBD.

Peter Higgins, MD, PhD, University of Michigan Health System, talked about how patients these days are often answering their own nutritional questions on the "Wild Wild West" of the Internet, so it's up to the experts to provide thorough answers to assuage their concerns.

At the 2015 Advances in Inflammatory Bowel Diseases (AIBD) meeting in Orlando, Florida, Peter Higgins, MD, PhD, the University of Michigan Health System shared his insight about the importance and value of careful nutritional guidance for IBD patients.

It’s been suggested that probiotics can help prevent relapses in ulcerative colitis, but a new analysis presented in a poster session at the 2015 Advances in Inflammatory Bowel Diseases conference (AIBD 2015) in Orlando, Florida argues that that’s not the case.

Measures in place to limit systemic steroid use for patients with inflammatory bowel disease are not as effective as they need to be. They should be replaced by a two-part model to examine drug utilization patterns that would separately consider factors associated with initiation and duration of therapy.

Hospitalization and mortality is more likely in elderly patients with inflammatory bowel disease (IBD) when compared to their younger counterparts. With 5-aminosalicylates (5-ASA) and corticosteroids becoming more popular in this age group, it’s not clear how they affect patients in the long run.

Eva Szigethy, MD, PhD, University of Pittsburgh discussed at the 2015 Advances in Inflammatory Bowel Diseases (AIBD) how to continue the conversation and implement methods to treat the burgeoning concern of opioid dependence among pediatric IBD patients.

Study results show that patients with ulcerative colitis who undergo hematopoietic stem cell transplantation (HSCT) had higher rates of opportunistic infections and inpatient mortality compared to transplant patients who did not have UC.

Miguel Regueiro, MD, University of Pittsburgh Medical Center, highlighted the hot topics in IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Researchers examined the possible connection between vitamin D levels and IBD in a cohort of African American patients with IBD and a control group of those patients’ African American healthy spouses and friends.

Fatigue is two to three times more likely to appear in patients with inflammatory bowel disease (IBD) than in healthy controls. Researchers from Østfold University College in Norway found that the common symptom can lead to additional interferences.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine continued to discuss the relevance of healthcare economics specific to IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine, discussed the progress made not only in the clinical care of IBD, but also in the basic science group and translational core at the 2015 Advances in Inflammatory Bowel Diseases meeting in Orlando, FL.

Sometimes when a patient with epilepsy has a seizure they may not even recognize it for any number of reasons. A device no bigger than a piece of gum which is being developed could help in that effort going forward.

When epilepsy patients use marijuana their memory test results may not be accurate, researchers report.

There are many factors to consider when treating patients with epilepsy, from the number of medications they take to the impact of the condition on their daily lives. All these factors can help determine their overall quality of life.